DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
New Agent Reduces Eye Bulging in Graves’ Orbitopathy, Offering New Hope for Patients
An experimental human monoclonal antibody dramatically reduced the most debilitating symptoms of Graves’ orbitopathy, including proptosis and double vision, giving new hope to patients that a treatment for thyroid eye disease may finally be within reach, according to a speaker at the AACE Annual Scientific and Clinical Congress.
According to new phase 3 data from the OPTIC trial presented here, adults with active Graves’ orbitopathy treated with teprotumumab (Horizon Pharma) for 21 weeks experienced an average proptosis reduction of 2.82 mm at 24 weeks compared with an average of 0.54 mm for those assigned to placebo, with between-group differences in proptosis reduction observed at all study time points, according to Raymond Douglas, MD, PhD, Director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center. Other symptoms associated with the disease, including inflammation, pain, swelling and redness, were also reduced for patients assigned teprotumumab vs. placebo, he said.


Related Content
-
People & PlacesUniversity of Miami Health SystemWe leverage the latest research complete...
-
Evidence & EducationQuality-of-Life Impairments Persist Six Months After Treatment of Graves’ Hyperthyroidism and Toxic Nodular Go...Background: The treatment of hyperthyro...
-
Evidence & EducationThe Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...
-
Evidence & EducationThyroidectomy as Primary Treatment Optimizes Body Mass Index in Patients With HyperthyroidismObjective: The purpose of this study wa...
-
Evidence & EducationNew Therapeutic Horizons for Graves’ HyperthyroidismGraves’ hyperthyroidism is characteriz...
-
Evidence & EducationPrevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves’ Disease By Early Initiatio...Background: Radioactive iodine (RAI) th...
-
Videos & VisualsShould I Consider Thyroidectomy for Graves’ Disease?https://www.youtube.com/watch?v=HuodaiVD...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.